A PHASE 1B/2A, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND EFFICACY OF AN ANTI-CD38 ANTIBODY DRUG CONJUGATE (STI-6129) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Study of STI-6129 in Patients with Relapse/Refractory Multiple Myeloma (RRMM)
Sponsor: Sorrento Therapeutics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAU0103
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: You are being asked to participate in this study because you have multiple myeloma that has either returned after your most recent treatment regimen or has not responded to your most recent treatment regimen. Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making antibodies that recognize and attack germs. In multiple myeloma, cancerous plasma cells grow in number in the bone marrow and crowd out healthy blood cells. The study drug STI-6129 is an antibody-drug conjugate that is designed to specifically attach to multiple myeloma cells and deliver a toxin into those cells to kill them. The purpose of this study is to find out if there are any side effects which prevent further use of STI-6129 in humans or if there is any change in your multiple myeloma as reflected by blood tests, and if there is any change in the symptoms of multiple myeloma.
Investigator
Rajshekhar Chakraborty, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with relapse/refractory multiple myeloma (RRMM)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162